Filing Details
- Accession Number:
- 0001209191-23-053939
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-10-31 16:11:28
- Reporting Period:
- 2023-10-28
- Accepted Time:
- 2023-10-31 16:11:28
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1654151 | Deciphera Pharmaceuticals Inc. | DCPH | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1325710 | L Matthew Sherman | C/O Deciphera Pharmaceuticals, Inc. 200 Smith Street Waltham MA 02451 | Evp & Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2023-10-28 | 8,244 | $0.00 | 92,988 | No | 4 | A | Direct | |
Common Stock | Disposition | 2023-10-30 | 2,360 | $12.02 | 90,628 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | S | Direct |
Footnotes
- On February 15, 2023, the Reporting Person was granted restricted stock units ("RSUs"), which vest upon the satisfaction of three performance criteria. On October 28, 2023, the Issuer's Compensation Committee confirmed that performance criteria two had been met, resulting in the vesting of 8,244 RSUs.
- This sale was to cover tax liabilities in the vesting of RSUs.